2,8-diamino-octanoic acid | 63648-14-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2,8-diamino-octanoic acid
• 英文别名: 2,8-Diamino-octansaeure；2,8-Diaminooctanoic acid
• CAS: 63648-14-6
• 化学式: C₈H₁₈N₂O₂
• 分子量: 174.243
• InChiKey: KMPBBRFCAYFTMR-UHFFFAOYSA-N

物化性质

• 沸点：
  340.0±32.0 °C(Predicted)
• 密度：
  1.069±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -3.2
• 重原子数：
  12
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  89.3
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,8-diamino-octanoic acid 、 氯甲酸苄酯 生成 N^η-Z-2,8-diaminooctanoic acid
  参考文献：
  名称：

  BOGER, JOSHUA S.;PAYNE, LINDA S.

  摘要：

  DOI：
• 作为产物：
  描述：

  8-氨基辛酸 在 盐酸 、 磺酰氯 、 碘 作用下， 生成 2,8-diamino-octanoic acid
  参考文献：
  名称：

  Takagi; Hayashi, Chemical and pharmaceutical bulletin, 1959, vol. 7, p. 96

  摘要：

  DOI：

文献信息

• [EN] FORMULATION AND METHOD OF PREPARATION<br/>[FR] FORMULATION ET PROCÉDÉ DE PRÉPARATION
  申请人：GE HEALTHCARE AS

  公开号：WO2019185607A1

  公开（公告）日：2019-10-03

  There is described formulations for human or animal administration and to a method of preparation thereof. In particular, there is described more stable pharmaceutical formulations, such as those for intravenous administration, and to a method of preparation thereof. There are also described lyophilised formulations having an active pharmaceutical ingredient (API), a buffering agent and a lyoprotectant, wherein the API is an imaging agent comprising at least one cMet binding peptide, suitable for optically imaging the mammalian body in vivo. Also described are a method of preparing a lyophilised formulation, a pharmaceutical composition, and a kit for the preparation of the pharmaceutical composition. Further described are methods of imaging using the formulation or pharmaceutical composition, such as in detection, diagnosis, surgery, staging, treatment, monitoring of treatment, monitoring of disease progression or monitoring therapy of conditions such as cancer.

  描述了用于人类或动物给药的配方以及其制备方法。特别是，描述了更稳定的药物配方，例如用于静脉给药的配方，以及其制备方法。还描述了冻干配方，其中包含一种活性药物成分（API）、缓冲剂和冻干保护剂，其中API是包含至少一种cMet结合肽的成像剂，适用于体内光学成像哺乳动物体。还描述了制备冻干配方的方法、药物组合物和用于制备药物组合物的工具包。此外，还描述了使用该配方或药物组合物进行成像的方法，例如在癌症的检测、诊断、手术、分期、治疗、治疗监测、疾病进展监测或治疗监测等方面。
• Diagnostic and therapeutic agents
  申请人：Taube Seija

  公开号：US20070258899A1

  公开（公告）日：2007-11-08

  Tumor targeting units are disclosed which have a peptide sequence C y —Y—G-F—X—W-G-Z-C yy (SEQ ID NO: 25), or a pharmaceutically or physiologically acceptable salt thereof. Tumor targeting agents are also disclosed having at least one targeting unit, directly or indirectly coupled to at least one effector unit. Diagnostic or pharmaceutical compositions having at least one targeting unit or at least one targeting agent, and targeting units or targeting agents for the preparation of a medicament for the treatment of cancer related diseases (including cancer), especially for the treatment of colon/colorectal cancer or its metastases are also disclosed.

  揭示了具有肽序列Cy—Y—G-F—X—W-G-Z-Cyy（序列ID编号：25）或其药学或生理上可接受的盐的肿瘤靶向单元。还披露了具有至少一个靶向单元的肿瘤靶向剂，直接或间接地偶联至至少一个效应单元。还披露了具有至少一个靶向单元或至少一个靶向剂的诊断或药物组合物，以及用于制备治疗癌症相关疾病（包括癌症）的药物的靶向单元或靶向剂，特别是用于治疗结肠/结直肠癌或其转移的靶向单元或靶向剂。
• [EN] CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS<br/>[FR] PEPTIDES CYCLIQUES POUR LA PROTECTION CONTRE LE VIRUS RESPIRATOIRE SYNCYTIAL
  申请人：VIROMETIX AG

  公开号：WO2018229156A1

  公开（公告）日：2018-12-20

  The present invention relates to a cyclic peptide, a conjugate comprising said cyclic peptide and a lipopeptide building block, a bundle of said conjugates, a synthetic virus-like particle comprising at least one bundle of conjugates and pharmaceutical compositions comprising the same. The present invention further relates to said cyclic peptide, said conjugate said bundle of conjugates, said synthetic virus-like particle and said pharmaceutical compositions for use as a medicament, preferably for use in a method for preventing of an infectious disease or reducing the risk of an infectious disease, more preferably for use in a method for preventing or reducing the risk of an infectious disease associated with or caused by a respiratory syncytial virus. In particular, the present invention relates to a cyclic peptide, wherein said cyclic peptide comprises an amino acid sequence (I), wherein said amino acid sequence (I) comprises the following amino acid sequence: X1-X2-X3-C4-X5-X6-X7-C8-X9-X10-X11-P12-I13-T14-N15-D16-Q17-K18-K19-L20-C21- X22-X23-X24-C25-X26-X27-X28-X29-X30 (SEQ ID NO: 1), wherein X1, X2, X3, X5, X6, X7, X9, X10, X11, X22, X23, X24, X26, X27, X28 and X29 are independently of each other an amino acid; C4, C8, C21 and C25 are independently of each other cysteine; P12 is proline; I13 is isoleucine; T14 is threonine; N15 is asparagine; D16 is aspartic acid; Q17 is glutamine; K18 and K19 are independently of each other lysine; L20 is leucine; and X30 is an amino acid or a deletion, wherein said cysteines C4 and C25 form a first disulfide bond and said cysteines C8 and C21 form a second disulfide bond.

  本发明涉及一种环肽，一种包含所述环肽和脂肽肽基的结合物，一束所述结合物，一种合成的类病毒颗粒，其中包括至少一个结合物束以及包含它们的制药组合物。本发明还涉及该环肽，该结合物，该结合物束，该合成的类病毒颗粒和该制药组合物作为药物的用途，优选用于预防传染病或降低传染病风险的方法，更优选用于预防或降低与呼吸道合胞病毒相关或由其引起的传染病的方法。特别地，本发明涉及一种环肽，其中所述环肽包括氨基酸序列(I)，其中所述氨基酸序列(I)包括以下氨基酸序列：X1-X2-X3-C4-X5-X6-X7-C8-X9-X10-X11-P12-I13-T14-N15-D16-Q17-K18-K19-L20-C21-X22-X23-X24-C25-X26-X27-X28-X29-X30(SEQ ID NO:1)，其中X1、X2、X3、X5、X6、X7、X9、X10、X11、X22、X23、X24、X26、X27、X28和X29分别是氨基酸；C4、C8、C21和C25分别是半胱氨酸；P12是脯氨酸；I13是异亮氨酸；T14是苏氨酸；N15是天冬氨酸；D16是天冬酸；Q17是谷氨酰胺；K18和K19分别是赖氨酸；L20是亮氨酸；X30是氨基酸或缺失，其中所述半胱氨酸C4和C25形成第一二硫键，所述半胱氨酸C8和C21形成第二二硫键。
• ISOTHIOCYANATE FUNCTIONAL SURFACTANT AND ASSOCIATED METHOD OF USE
  申请人：Silver Michael E.

  公开号：US20170037000A1

  公开（公告）日：2017-02-09

  An isothiocyanate functional surfactant, wherein the protonated form of said surfactant is represented by the following chemical structure: wherein X includes an integer ranging from approximately 1 to approximately 25, and wherein Y includes an integer ranging from approximately 6 to approximately 25.

  一种异硫氰酸酯功能表面活性剂，其中所述表面活性剂的质子化形式由以下化学结构表示：其中X包括从大约1到大约25的整数，Y包括从大约6到大约25的整数。
• [EN] METHOD FOR TREATING SKIN CANCER<br/>[FR] MÉTHODE DE TRAITEMENT DU CANCER DE LA PEAU
  申请人：WILLIAM M YARBROUGH FOUNDATION

  公开号：WO2014018874A1

  公开（公告）日：2014-01-30

  A method for treating skin cancer including the steps of applying an isothiocyanate functional surfactant to an area affected by skin cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.

  一种治疗皮肤癌的方法，包括将一种异硫氰酸酯功能表面活性剂涂抹在受皮肤癌影响的区域上，其中异硫氰酸酯功能表面活性剂包括至少一个与异硫氰酸酯功能表面活性剂的脂肪族和/或芳香族碳原子相关的异硫氰酸酯功能基。